

marie Aurigemma, Ph.D.

f, Drug Development Section

e of Biodefense, Research Resources, and Translational Research

, NIAID, NIH


Background

Current position found via USAjobs in 2009

Moved from NCI, DCTD to NIAID, DMID

- -Different focus: Cancer vs. Infectious Diseases
- Common ground: Drug Development, Translational Research

7 staff – 5 hired since 2009 (2010, 2012, 2014, 2015, 2016)



xample: 2015 HSA Recruitment

| | A | В |
|-----|--|---|
| | Background in Genetics, in general and Human Genetics, | |
| | in particular, with research concentrations in Breast | |
| | Cancer and Vaccine Development, Other Cancer Biology, | |
| 72 | Genetics, Cellular & Molecular Bio | Genetics and Human Genetic |
| | I manage a research grant portfolio in biospecimen | Human Molecular Genetics - |
| | research and cancer clinical trials, with expertise in | identify novel cytokine genes |
| | Genomics, Proteomics, Bioinformatics, Systems | for potential HIV drug |
| 73 | Biology and translational sciences. | development. |
| 13 | | development. |
| | I am a Research Biologist/Toxicologist with >25 years | |
| | experience in Academic and Government. Expertise in | Endocrinology -Reproductive |
| | examining neurotoxicity/neurodegeneration, behavioral | developmental and |
| 74 | related health aspects. | neuroendocrinology. |
| | cognitive neuroscience, meditation, fMRI, neuroimaging, | |
| | attention, mind wandering, contemplative studies, | |
| | psychophysiology, cognitive assessment, psychiatry, | |
| 75 | schizophrenia, molecular, gene expression | Neuroscience |
| | International Relations & Policy; Global Health; Pain | Ph.D. in Clinical |
| | (Cancer, Acute, Chronic); Health Disparities; PsychoSocial | Neuropsychology, Specialize |
| | Influences on Disease; Predicting Outcome; | Training: Genetics, |
| 76 | Psychophysiology; Genetics, PK/PD/PGx of Pain | Pharmacogenomics of Pain |
| 10 | Emerging Infectious Disease, virology, RNA viruses, bat- | Lobtained a PhD in an |
| | | |
| | borne & vector-borne dis, epidemiology, vaccine | interdisciplinary program for |
| | development, viral therapeutic development, molecular | Emerging Infectious Disease |
| 77 | biology, bacteriology, micro. animal model | My training and postdoctoral |
| | Innovative and results-oriented independent veterinary | As a veterinary surgeon, my |
| | scientist with expertise in pharmacokinetic animal | interests were in the biology o |
| | modeling, animal surgery and in vivo videomicroscopy | tumor metastasis such as |
| 78 | imaging in pediatric cancer metastasis. | animal biology in the |
| | Conducted microbiological research (mainly | Ph.D. in microbiology at |
| | bacteriology)and gained expertise in microbial | Cornell University, followed b |
| 73 | pathogenesis, vaccine development, microbial physiology, | |
| | Metabolic disorders, lipid metabolism, fatty liver disease | Thioropiological reptaron at |
| | (alcoholic and non-alcoholic), cardiovascular disease, | |
| | atherosclerosis, diabetes and obesity, genetics/genomics, | |
| | atheroscierosis, diabetes and obesity, genetics/genomics, molecular/Cell Biology. | Ph.D. in Biological Sciences |
| 80 | | டா.ம். in biological sciences |
| | I am an expert in lung macrophage function and host | |
| | defense against opportunistic bacterial and viral infections | 5.5 |
| 81 | following autologous bone marrow transplantation. | Ph.D. in Immunology |
| | Research scientist with experience in developing, leading, | My major field of study include |
| | and conducting multi-disciplinary scientific studies in | biomedical research, |
| 82 | cancer biology, toxicology, health policy, and public health. | toxicology, and colon cancer |
| | Basic and translational/preclinical pharmacology, | |
| | neuroscience, and vascular biology, with disease | |
| | emphases on addiction, psychiatric illness, hypertension, | |
| 83 | stroke, and cancer. | Pharmacology |
| 84 | N/a | N/a |
| | Reprogramming of somatic cells to generate induced | I did my PhD in Zoology with |
| | pluripotent stem cells (iPSCs) and study the therapeutic | the specialization in |
| | potential of these cells by using the mouse lung injury and | Immunology and Inflammator |
| 0.5 | | |
| 85 | myocardial infarction models | mechanism. |
| | B. A. C. | My graduate studies focused |
| | Pediatric upper respiratory tract infections, transcriptional | on manganese-dependent |
| 86 | regulation, bacterial pathogenesis and animal models. | regulation in Streptococcus |
| | - Virology: Infection and oncogenesis by tumor viruses, - | L |
| | Immunology: T cell activation, memory, autoimmune | Molecular Microbiology and |
| 87 | disease, immunotherapy | Immunology |
| | Biochemistry, immunology, drug development for cancer | Ph.D in biochemistry; |
| | and inflammation/autoimmune diseases, IND filing, GLP | postdoctoral training in growl |
| 88 | compliant bioassay and pharmacokinetics assay | factor receptor pharmacolog |
| | I have worked independently in planning, organizing, and | |
| | conducting biomedical research in the fields of | |
| | dermatology, inflammatory disease, cancer biology and | I received my PhD degree in |
| 89 | gastroenterology (Gl peptides). | Cell and Molecular Biology. |
| 03 | gestroenterology (or peptides). | Treceived my PhD from the |
| | My areas of scientific expertise include (in order of most to | |
| | | Department of Medical |
| | | R. War Land and R. William - D. Carlon - A. |
| 90 | modest knowledge: | Molecular Microbiology & |
| 90 | | |

- >Applicants = 212
- ➤ Molecular Biology = 75
- **➢ Biochemistry = 70**
- ➤ Cell biology = 44
- ➤ Microbiology = 35
- ►Infectious Disease = 20
- ➤Translational Research = 11
- >Pharmacology = 26
- ▶ Drug Development = 8
- ➤ Vaccine Development = 14
- >Animal Model = 8
- ▶Pharmaceutical = 2
- ►GMP, GLP, Regulatory Affairs = 2

etting Through the Secondary Screen

scribe the accomplishments and outcomes, not t skills!

K: Performed chemical synthesis, animal efficacy studies, PK ample analysis

estimates and synthesized drug analogs and optimized osing regimen in a model of infectious disease; developed an assays used to diagnose early disease stage and to establish asma concentrations of drug in infected animals. Data helped upport first-in-human clinical trials.

etting Through the Secondary Screen

scribe the accomplishments/outcomes, not just s!

: Served on review committee

TER: As part of review team, identified gaps in program areas; veloped and implemented strategy to fill gaps which resulted in hanced programmatic success rate.

: Presented scientific data at conferences; described mechanism of tion

TER: Upon presenting scientific data at conference, established laborations to further advance scientific inquiry in key areas leading identification of target mechanism and 2 additional publications.

Interviewing

Find out as much as you can ahead of time:

- Mission
- Commonalities; colleagues, technology
- Future directions
- Emphasize problem-solving, creativity, independence
- Explain your talents and goals (be honest)
- Explain why the job attracted you and what you can contribute

